Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck (MRK) stock gains as company enters a global licensing deal with Hansoh Pharma to develop an oral obesity drug. Read ...

The parents of seven-year-old Gungun (pseudonym) finally saw a light at the end of the tunnel when they heard that a foreign ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on MRK stock, giving a Buy rating on December 11.Pick the best ...